Casdatifan, a potential best-in-class HIF-2a inhibitor, demonstrated 12.2 months median progression-free survival (mPFS) and 18-month landmark PFS of 43% in a pooled analysis of 121 patients with late ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback